I Continuing Review

A011202, A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy (Protocol Version Date 07/12/21)

II Continuing Review

A031102, A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors (Protocol Version Date 07/23/21)

III Continuing Review

A041202, A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (≥ 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL) (Protocol Version Date 03/20/19)

IV Continuing Review

A081801, Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO) (Protocol Version Date 10/25/21)

V Continuing Review

E1912, A Randomized Phase III Study of Ibrutinib (PCI-32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL) (Protocol Version Date 05/25/18)

VI Continuing Review

GOG-0213, A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (Or Gemcitabine) Alone or in Combination with Bevacizumab (NSC #704865, IND #113912) followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive,
Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865, IND #113912)(12/19/2011) (10/01/12) NCT# 00565851  (Protocol Version Date 11/16/18)

VII Continuing Review

GOG-0263, Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy  (Protocol Version Date 05/12/20)

VIII Continuing Review


IX Continuing Review

NRG-GY019, A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum  (Protocol Version Date 12/10/19)

X Continuing Review


XI Continuing Review

S1403, A Randomized Phase II Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) (BI 1200.124)  (Protocol Version Date 07/29/20)
XII Continuing Review

S1607, A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and Pembrolizumab (MK-3475) (NSC-776864) in Patients with Advanced Melanoma who have Progressed on ANTI-PD1/L1 Based Therapy (Protocol Version Date 10/15/21)

XIII Continuing Review

S1608, Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma (Protocol Version Date 07/02/21)

XIV Continuing Review

S1905, A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL) (Protocol Version Date 07/28/21)

XV Continuing Review

S1925, Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study (Protocol Version Date 08/06/21)

XVI Continuing Review

S1929, Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC) (Protocol Version Date 11/12/21)

XVII Continuing Review

S1933, A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status (Protocol Version Date 06/01/21)
XVIII New Study - Initial Review

A032101, A Phase 2 Trial of ADT Interruption in Patients Responding Exceptionally to AR-Pathway Inhibitor in Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): A-DREAM (Protocol Version Date 11/23/21)

XIX New Study - Initial Review

EA9213, A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL) (Protocol Version Date 12/02/21)

XX Amendment

EA6134, DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial (Protocol Version Date 11/19/21)

XXI Amendment

S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC STUDY) (Protocol Version Date 11/16/21)